NeuroBo Pharmaceuticals
Latest round
- Series B
Last raised
- Aug 2019
Total raised
- $37M
Investors
- 1
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc.NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology firm formed in 2017 and headquartered in Boston, US. It specializes in therapies for cardiometabolic conditions. The company underwent a reverse merger with Gemphire Therapeutics Inc. in December 2019, becoming a publicly listed entity.000 mn. The company has engaged in 5 deals, with the most recent deal occurring on January 19, 2021.NeuroBo Pharmaceuticals, Inc. offers two primary product candidates: DA-1726, a dual oxyntomodulin (OXM) analog agonist designed to stimulate both glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), and DA-1241, a G-Protein-Coupled Receptor 119 (GPR119) agonist aimed at treating MASH.In 2023, NeuroBo Pharmaceuticals, Inc.88 mn. Revenue is generated through partnerships with healthcare providers, research institutions, and pharmaceutical companies, primarily through collaboration agreements and licensing arrangements for its proprietary products, DA-1726 and DA-1241, in exchange for milestone payments and royalties.NeuroBo Pharmaceuticals, Inc. plans to expand its portfolio by advancing DA-1726 and DA-1241 through clinical trials, with a focus on securing regulatory approval. The company aims to target both North American and European markets for product distribution. Following the successful fundraising in October 2021, the company is well-positioned to capitalize on new partnerships and enhance its market reach as it continues to develop therapies for cardiometabolic diseases.
Who invested in NeuroBo Pharmaceuticals
1 investor across 2 rounds
See all investors in NeuroBo Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about NeuroBo Pharmaceuticals
Who invested in NeuroBo Pharmaceuticals?
NeuroBo Pharmaceuticals has 1 investor on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has NeuroBo Pharmaceuticals raised?
NeuroBo Pharmaceuticals has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did NeuroBo Pharmaceuticals last raise money?
NeuroBo Pharmaceuticals's most recent round on record is a Series B, in Aug 2019.
What does NeuroBo Pharmaceuticals do?
NeuroBo Pharmaceuticals is a biotechnology company.
Where is NeuroBo Pharmaceuticals headquartered?
NeuroBo Pharmaceuticals is headquartered in Boston, US.
Which VCs invest in companies like NeuroBo Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at NeuroBo Pharmaceuticals's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like NeuroBo Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.